Search Results - "glucose"

PI3K/AKT signaling In cancer

Table of Contents: “…Contents: PI3K/AKT signal transduction pathway -- Tumors with frequent dysregulation of PI3K signalling -- Modalities for inhibiting PI3K-AKT signaling currently in development -- AKT1/2 inhibitor (Merck) -- PI3K/AKT in breast cancer -- AKTi-1/2 inhibits AKT signaling and causes G1 arrest -- The Herceptin-resistant -- Effect of AKT inhibition on glucose levels -- Mutated elements in mitogenic signaling pathways in tumors -- Coexistent K-Ras or B-Raf mutation -- Genes encoding several components of mitogenic signaling pathways are mutationally activated in tumors -- Integrators of multiple signaling pathways (OR-gates) -- The effects of combined inhibition of AKT and MAPK on the phosphorylation of translational regulatory proteins -- Knockdown of 4EBP1 expression -- Feedback inhibition of insulin/IGF-1 signaling -- The concept of feedback -- Clinical effects of Rapamycin-like drugs -- mTORC1 vs. …”
Get full text
Series

PI3K/AKT signaling In cancer

Table of Contents: “…Contents: PI3K/AKT signal transduction pathway -- Tumors with frequent dysregulation of PI3K signalling -- Modalities for inhibiting PI3K-AKT signaling currently in development -- AKT1/2 inhibitor (Merck) -- PI3K/AKT in breast cancer -- AKTi-1/2 inhibits AKT signaling and causes G1 arrest -- The Herceptin-resistant -- Effect of AKT inhibition on glucose levels -- Mutated elements in mitogenic signaling pathways in tumors -- Coexistent K-Ras or B-Raf mutation -- Genes encoding several components of mitogenic signaling pathways are mutationally activated in tumors -- Integrators of multiple signaling pathways (OR-gates) -- The effects of combined inhibition of AKT and MAPK on the phosphorylation of translational regulatory proteins -- Knockdown of 4EBP1 expression -- Feedback inhibition of insulin/IGF-1 signaling -- The concept of feedback -- Clinical effects of Rapamycin-like drugs -- mTORC1 vs. …”
Get full text
Series

PI3K/AKT signaling In cancer

Table of Contents: “…Contents: PI3K/AKT signal transduction pathway -- Tumors with frequent dysregulation of PI3K signalling -- Modalities for inhibiting PI3K-AKT signaling currently in development -- AKT1/2 inhibitor (Merck) -- PI3K/AKT in breast cancer -- AKTi-1/2 inhibits AKT signaling and causes G1 arrest -- The Herceptin-resistant -- Effect of AKT inhibition on glucose levels -- Mutated elements in mitogenic signaling pathways in tumors -- Coexistent K-Ras or B-Raf mutation -- Genes encoding several components of mitogenic signaling pathways are mutationally activated in tumors -- Integrators of multiple signaling pathways (OR-gates) -- The effects of combined inhibition of AKT and MAPK on the phosphorylation of translational regulatory proteins -- Knockdown of 4EBP1 expression -- Feedback inhibition of insulin/IGF-1 signaling -- The concept of feedback -- Clinical effects of Rapamycin-like drugs -- mTORC1 vs. …”
Get full text
Series